RxDoctor Payments Data

David Schaefer, MD

Psychiatry · Saint George, UTNPI 1881891224

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $238 of the $349 with a category attached, or 68.1%. 9 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 31.9% of the total.

$349in general payments, 2019–2025

Across 15 payments — averaging $23.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$111
  • Johnson & Johnson$42
  • E.r. Squibb & Sons, L.L.C.$40
  • Otsuka America Pharmaceutical, Inc.$33
  • Alkermes, Inc.$31
  • Lundbeck LLC$31
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$23868%
  • Education$11132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$349 in reported general payments places this provider in the 75th percentile of 231 psychiatry providers in Utah.

See all psychiatry providers in Utah

Medicare billing

Part B allowed, 2024
$16,677
Medicare patients
39
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate23$216,843
Invega SustennaPaliperidone Palmitate56$194,770
Abilify MaintenaAripiprazole40$113,274
AustedoDeutetrabenazine13$100,143
IngrezzaValbenazine Tosylate12$98,273
VraylarCariprazine Hcl44$63,020
AristadaAripiprazole Lauroxil27$52,854
Seroquel XrQuetiapine Fumarate26$22,294
TrintellixVortioxetine Hydrobromide27$16,900
VivitrolNaltrexone Microspheres11$16,895
SecuadoAsenapine11$16,210
Aripiprazole165$12,403
Asenapine Maleate45$9,578
Paliperidone ErPaliperidone25$8,715
Clozapine120$7,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$42$411,61379 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$33$113,27440 claims
Teva Pharmaceuticals USA, Inc.Austedo$111$100,14313 claims
Neurocrine Biosciences, Inc.Ingrezza$26$98,27312 claims
Alkermes, Inc.Aristada, Vivitrol$31$69,74938 claims
AbbVieVraylar$22$63,02044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 231 psychiatry providers in Utah.

Other psychiatry in Saint George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →